Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) ("Biodexa" or "Company"), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products ...
BENGALURU, India, Oct. 27, 2025 /PRNewswire/ -- Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its ...
Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “Company”), a clinical stage biopharmaceutical company developing a clinical stage biopharmaceutical company developing innovative products ...
Syngene International, a global contract research, development, and manufacturing organization (CRDMO), reports that that its newly upgraded biologics facility (Unit 3) in Bangalore, India, will be ...
Monoclonal antibodies (mAbs) have revolutionized modern medicine, offering precision therapies for cancer, autoimmune disorders, infectious diseases, and numerous other advantages. The global mAb ...
Indian contract research, development and manufacturing organization Syngene International has appointed Siddharth Mittal as managing director and chief executive.
Bioconjugation capability will complement commercial payload, linker and monoclonal antibodies services BENGALURU, India, Oct. 27, 2025 /PRNewswire/ -- Syngene International, a global contract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results